PRO-AH-002

PRO-AH-002 is a preclinical-stage IgY antibody-based therapeutic being developed by Prodigy Biotech for the treatment of alcohol-associated hepatitis (AH). As part of Prodigy's pipeline of avian-derived antibody therapeutics, PRO-AH-002 is designed to modulate the gut-liver axis by selectively targeting microbial pathogens or toxins in the gastrointestinal tract. This approach aims to neutralize specific drivers of liver inflammation and injury associated with alcohol use without systemic exposure or broad disruption of the gut microbiome. While the specific molecular target for PRO-AH-002 has not been disclosed, it follows the company's platform technology of using chicken-derived immunoglobulin-Y (IgY) to provide a non-invasive treatment option for liver diseases.